|
|
Prepublished online as a Blood First Edition Paper on July 3, 2003; DOI 10.1182/blood-2003-03-0877.
 Previous Article | Table of Contents | Next Article 
Blood, 1 October 2003, Vol. 102, No. 7, pp. 2373-2378
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation–based conditioning regimen to prevent disease progression in patients with high disability scores
Richard K. Burt,
Bruce A. Cohen,
Eric Russell,
Kenneth Spero,
Akash Joshi,
Yu Oyama,
William J. Karpus,
Kehuan Luo,
Borko Jovanovic,
Ann Traynor,
Karyn Karlin,
Dusan Stefoski, and
William H. Burns
From the Departments of Neurology, Medicine—Division of Immunotherapy, Radiology—Neuroradiology, Pathology, and Department of Preventive Medicine, Northwestern University Medical School, Chicago, IL; and Department of Neurology, Rush Saint Lukes Medical Center, Chicago, IL.
There were 21 patients with rapidly progressive multiple sclerosis (MS) treated on a phase 1/2 study of intense immune suppressive therapy and autologous hematopoietic stem cell (HSC) support with no 1-year mortality. Following transplantation, one patient had a confirmed acute attack of MS. Neurologic progression defined by the expanded disability status scale (EDSS) did not increase in disability by 1.0 or more steps in any of 9 patients with a pretransplantation EDSS of 6.0 or less. In 8 of 12 patients with high pretransplantation disability scores (EDSS > 6.0), progressive neurologic disability as defined by at least a 1-point increase in the EDSS has occurred and was manifested as gradual neurologic deterioration. There were 2 patients with a pretransplantation EDSS of 7.0 and 8.0 who died from complications of progressive disease at 13 and 18 months following treatment. Our experience suggests that intense immune suppression using a total body irradiation (TBI)-based regimen and hematopoietic stem cell transplantation (HSCT) are not effective for patients with progressive disease and high pretransplantation disability scores. Further studies are necessary to determine the role of intense immune suppressive therapy and HSC support in ambulatory patients with less accumulated disability and more inflammatory disease activity. Specifically, more patients and longer follow-up would be required in patients with an EDSS of 6.0 or less before drawing conclusions on this subgroup. (Blood. 2003;102:2373-2378)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J Fagius, J Lundgren, and G Oberg
Early highly aggressive MS successfully treated by hematopoietic stem cell transplantation
Multiple Sclerosis,
February 1, 2009;
15(2):
229 - 237.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. L. Barnard, A. P. Chidgey, C. C. Bernard, and R. L. Boyd
Androgen depletion increases the efficacy of bone marrow transplantation in ameliorating experimental autoimmune encephalomyelitis
Blood,
January 1, 2009;
113(1):
204 - 213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Mondria, C H J Lamers, P A W t. Boekhorst, J W Gratama, and R Q Hintzen
Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
September 1, 2008;
79(9):
1013 - 1015.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, Y. Loh, W. Pearce, N. Beohar, W. G. Barr, R. Craig, Y. Wen, J. A. Rapp, and J. Kessler
Clinical Applications of Blood-Derived and Marrow-Derived Stem Cells for Nonmalignant Diseases
JAMA,
February 27, 2008;
299(8):
925 - 936.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Loh, Y. Oyama, L. Statkute, K. Quigley, K. Yaung, E. Gonda, W. Barr, B. Jovanovic, R. Craig, D. Stefoski, et al.
Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used
Blood,
March 15, 2007;
109(6):
2643 - 2548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Saccardi, T Kozak, C Bocelli-Tyndall, A Fassas, A Kazis, E Havrdova, E Carreras, A Saiz, B Lowenberg, P A. te Boekhorst, et al.
Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database
Multiple Sclerosis,
November 1, 2006;
12(6):
814 - 823.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Daumer, L M Griffith, W Meister, R A Nash, and J S Wolinsky
Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation
Multiple Sclerosis,
April 1, 2006;
12(2):
174 - 179.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J P A Samijn, P A W te Boekhorst, T Mondria, P A van Doorn, H Z Flach, F G A van der Meche, J Cornelissen, W C Hop, B Lowenberg, and R Q Hintzen
Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
January 1, 2006;
77(1):
46 - 50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Herrmann, S. Gaertner, C. Stadelmann, J. van den Brandt, R. Boscke, W. Budach, H. M. Reichardt, and R. Weissert
Tolerance induction by bone marrow transplantation in a multiple sclerosis model
Blood,
September 1, 2005;
106(5):
1875 - 1883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Mancardi, A. Murialdo, P. Rossi, F. Gualandi, G. Martino, A. Marmont, F. Ciceri, A. Schenone, R. C. Parodi, E. Capello, et al.
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis
Multiple Sclerosis,
June 1, 2005;
11(3):
367 - 371.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. K. Burt, B. Cohen, J. Rose, F. Petersen, Y. Oyama, D. Stefoski, G. Katsamakis, E. Carrier, T. Kozak, P. A. Muraro, et al.
Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
Arch Neurol,
June 1, 2005;
62(6):
860 - 864.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Saccardi, G. L. Mancardi, A. Solari, A. Bosi, P. Bruzzi, P. Di Bartolomeo, A. Donelli, M. Filippi, A. Guerrasio, F. Gualandi, et al.
Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life
Blood,
March 15, 2005;
105(6):
2601 - 2607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Muraro, D. C. Douek, A. Packer, K. Chung, F. J. Guenaga, R. Cassiani-Ingoni, C. Campbell, S. Memon, J. W. Nagle, F. T. Hakim, et al.
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients
J. Exp. Med.,
March 7, 2005;
201(5):
805 - 816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Rizvi and K. Bashir
Other therapy options and future strategies for treating patients with multiple sclerosis
Neurology,
December 28, 2004;
63(12_suppl_6):
S47 - S54.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. M Healey, S. Z Pavletic, J. Al-Omaishi, M P. Leuschen, S. J Pirruccello, M. L Filipi, C. Enke, M. M. Ursick, F. Hahn, J D Bowen, et al.
Discordant functional and inflammatory parameters in multiple sclerosis patients after autologous haematopoietic stem cell transplantation
Multiple Sclerosis,
June 1, 2004;
10(3):
284 - 289.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. S. Freedman and H. L. Atkins
Suppressing immunity in advancing MS: Too much too late, or too late for much?
Neurology,
January 27, 2004;
62(2):
168 - 169.
[Full Text]
[PDF]
|
|
|
|
|
